🇺🇸 FDA
Patent

US 9839688

Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

granted A61KA61K2039/505A61K31/352

Quick answer

US patent 9839688 (Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer) held by Provectus Pharmatech, Inc. expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Provectus Pharmatech, Inc.
Grant date
Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/505, A61K31/352, A61K31/365, A61K38/193